Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent

Informations

• Publié par: frost-sullivan
• Nombre de lectures: 9
• Langue: English

Extrait

Frost & Sullivan: European Bipolar

Therapeutics Market Slows Down in the Short

Term As Key Blockbuster Drugs Go Off Patent

PR Newswire

LONDON, July 5, 2012

- New drug formulations and strong product pipelines expected to

restore growth beyond 2013

LONDON

,

July 5, 2012

/PRNewswire/ -- Patent expiry of key blockbuster atypical

antipsychotic drugs is likely to cause a decline in growth of the European

bipolar disorder therapeutics market until 2013. However, approval of new

drugs and improved depot formulations are expected to present growth

opportunities from 2014 to 2018.

New analysis from Frost & Sullivan (http://www.pharma.frost.com),

Analysis of

the European Bipolar-disorder Therapeutics Market

, finds that the

market earned revenues of

$1.20 billion

in 2011 and estimates this to reach

approximately

$1.22 billion

in 2018, at a compound annual growth rate (CAGR)

of 0.2 percent.

Patent expiry of several key blockbuster atypical antipsychotics, including

Seroquel from AstraZeneca, the only approved atypical antipsychotic for both

bipolar mania and depression, is one of the key challenges for the market

participants.

"As generic equivalents of these blockbuster drugs reach the market, drug

prices are expected to fall between 30-60 percent, causing an overall decrease

of 10.1 percent in the European bipolar disorder therapeutics market until

2013," noted Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram.

Nonetheless, the high levels of unmet therapeutic needs present significant

market opportunities and business potential. Over three million people have

been diagnosed with some form (mania, hypomania or depression) of bipolar

disorder in

Europe

; this number is estimated to double by 2018. Most of the

currently approved drugs focus on the treatment of acute mania or hypomania,

which means that drugs targeting bipolar depression are the need of the hour.

"Any initiative to develop new and improved drug formulations – particularly

depot formulations of atypical antipsychotics that improves the efficacy, safety

and overall performance of the drug – will bear fruit in the coming years," said

Chidambaram. "Increasing investments in R&D and the commercialisation of

four potential product candidates within the next few years are expected to

confer bright growth prospects."

Strategic alliances and collaborations among large, specialty pharmaceutical

companies and technology providers will be the key tool for companies to

expand their global footprint and increase market shares.

Within the European Union,

Germany

is expected to remain the largest bipolar-

disorder therapeutics market while

Italy

and

Spain

grow at relatively fast rates.

If you are interested in more information on this study, please send an e-mail

with your contact details to Janique Morvan, Corporate Communications, at

[e-mail].

Analysis of the European Bipolar-disorder Therapeutics Market

is part